A Membrane‐Targeted Photosensitizer Prevents Drug Resistance and Induces Immune Response in Treating Candidiasis

• DOI: 10.1002/advs.202207736
• Publication Date: 2023-10-25T02:04:56Z
• Authors: Ming‐Yu Wu; Xiaoyu Xu; Rui Hu; Qingrong Chen; Luojia Chen; Yuncong Yuan; Jie Li; Li Zhou; Shun Feng; Lianrong Wang; Shi Chen; Meijia Gu
• Keywords: drug resistance; photosensitizer; Science; Q; candidiasis; photodynamic therapy; immune response; Research Articles; 3. Good health

Abstract Candida albicans ( C. ), a ubiquitous polymorphic fungus in humans, causes different types of candidiasis, including oral candidiasis (OC) and vulvovaginal (VVC), which are physically mentally concerning financially costly. Thus, developing alternative antifungals that prevent drug resistance induce immunity to eliminate biofilms is crucial. Herein, novel membrane‐targeted aggregation‐induced emission (AIE) photosensitizer (PS), TBTCP‐QY, developed for highly efficient photodynamic therapy (PDT) candidiasis. TBTCP‐QY has high molar absorption coefficient an excellent ability generate 1 O 2 •OH, entering the interior due its permeability. Furthermore, can efficiently inhibit biofilm formation by suppressing expression genes related adhesion ALS3 , EAP1 HWP1 invasion SAP1 SAP2 MDR1 ) also advantageous eliminating potential fungal treat clinical infectious diseases. TBTCP‐QY‐mediated PDT targets OC VVC vivo mouse model, induces immune response, relieves inflammation, accelerates healing mucosal defects combat infections caused clinically isolated fluconazole‐resistant strains. Moreover, demonstrates biocompatibility, suggesting applications treatment VVC.